Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.

Details

Title
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
Author
Débora Leite Campos 1 ; Demarqui, Fernanda Manaia 1 ; Solcia, Mariana Cristina 1 ; de Souza, Paula Carolina 1   VIAFID ORCID Logo  ; Pedro Ivo da Silva Maia 2   VIAFID ORCID Logo  ; Deflon, Victor Marcelo 2 ; Fernando Rogério Pavan 1   VIAFID ORCID Logo 

 Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University—UNESP, Araraquara 14800-903, Brazil 
 Institute of Exact, Natural Sciences and Education, Triangulo Mineiro Federal University—UFTM, Uberaba 38064-200, Brazil 
First page
2398
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
22279059
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2728434612
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.